

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Grand Pharmaceutical and Healthcare Holdings Limited

遠大醫藥健康控股有限公司*
(incorporated in Bermuda with limited liability)
(Stock Code: 00512)

**POLL RESULTS OF THE SPECIAL GENERAL MEETING
HELD ON 17 AUGUST 2018**

Reference is made to the circular (the “**Circular**”) of China Grand Pharmaceutical and Healthcare Holdings Limited (the “**Company**”) dated 26 July 2018 and all resolutions proposed in the notice of special general meeting (the “**Notice**”) contained therein. Unless stated otherwise, capitalised terms used herein shall have the same meanings as those defined in the Circular.

POLL RESULTS

The Board announces that the resolution proposed was duly passed by way of poll at the SGM of the Company held on 17 August 2018.

As at the date of the SGM, the total number of issued shares in the Company was 2,306,984,531 Shares. As disclosed in the Circular, CDH Genetech and its close associates, who in aggregate held 108,408,000 Shares, were required to and had abstained from voting on the resolution at the SGM. Accordingly, the total number of Shares entitling the Shareholders to attend and vote for or against the resolution at the SGM was 2,198,576,531 Shares. Save as disclosed above, there was no Share entitling the holder to attend and abstain from voting in favour of the resolution at the SGM as set out in Rule 13.40 of the Listing Rules, and there was no Share the holder of which was required under the Listing Rules to abstain from voting at the SGM. Save as disclosed above, there was no restriction on Shareholders to cast votes on the resolution at the SGM. No Shareholder had indicated in the Circular of his intention to vote against or to abstain from voting on the resolution at the SGM.

The poll results in respect of all the resolution proposed at the SGM were as follows:

ORDINARY RESOLUTION (Note)		Number of Shares represented by votes cast (and percentage of total number of Shares represented by votes cast)	
		For	Against
1.	To approve, confirm and ratify the execution and delivery of the Scheme Implementation Deed and the Company’s participation in the	1,424,271,418 (99.75%)	3,631,588 (0.25%)

	Acquisition, and to authorise any one or more of the Directors to do all things necessary for implementation of the aforesaid.		
--	--	--	--

Note: Full text of the resolution is set out in the Notice.

As more than 50% of the votes were cast in favour of the proposed resolution, the resolution was duly passed as ordinary resolution by way of poll at the SGM.

The Company's auditors, HLB Hodgson Impey Cheng Limited, were appointed as the scrutineer at the SGM for the purpose of vote-taking.

By order of the Board
**China Grand Pharmaceutical and
Healthcare Holdings Limited**
Liu Chengwei
Chairman

Hong Kong, 17 August 2018

As at the date of this announcement, the Board comprises four executive directors, namely, Mr Liu Chengwei, Mr Hu Bo, Dr Shao Yan and Dr Niu Zhanqi and two independent non-executive directors, namely, Ms So Tosi Wan, Winnie and Dr Pei Geng.

** For identification purpose only*